home » department of neurology » department of neurology - publications 2015

Department of Neurology - Publications 2015

  1. Elamin M, Lonergan R, Killeen RP, O'Riordan S, Tubridy N, McGuigan C.
    Posterior cortical and white matter changes on MRI in anti-AMPA receptor antibody encephalitis. Neurol Neuroimmunol Neuroinflamm. 2015 May 21;2(4):e118.
  2. Broderick N, Farrell C, Tubridy N. Should we call the neurologist? The value and cost of a growing neurology consultation service.
    Ir J Med Sci. 2015 Jun 4. [Epub ahead of print]
  3. Rowan CR, Tubridy N, Cullen G. Multifocal Motor Neuropathy Associated with Infliximab. J Crohns Colitis. 2015 Jul 29. pii: jjv137. [Epub ahead of print]
  4. Greene BR, Rutledge S, McGurgan I, McGuigan C, OConnell K, Caulfield B, Tubridy N. Assessment and Classification of Early-Stage Multiple Sclerosis With Inertial Sensors:
    Comparison Against Clinical Measures of Disease State
    . IEEE J Biomed Health Inform. 2015 Jul;19(4):1356-61.
  5. Lonergan R, Kinsella K, Fitzpatrick P, Duggan M, Jordan S, Bradley D, Hutchinson M, Tubridy N. Unmet needs of multiple sclerosis patients in the community. Mult Scler Relat Disord. 2015 Mar; 4 (2):144-50.
  6. Ziemssen T, Bajenaru OA, Carrá A, de Klippel N, de Sá JC, Edland A, Frederiksen JL, Heinzlef O, Karageorgiou KE, Lander Delgado RH, Landtblom AM, Macías Islas MA, Tubridy N, Gilgun-Sherki Y. A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting
    to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial
    . J Neurol. 2014 Nov;261(11):2101-11.
  7. O'Toole O, Murphy O, O'Dwyer J, Lonergan R, Keogh B, Tubridy N, Lynch T, Farrell M. Paraneoplastic dentate ganglionopathy: clinical and neuroimmunologic studies. Clin Neuropathol. 2015 January/February;34(1):34-38
  8. Kuhle J, Hardmeier M, Disanto G, Gugleta K, Ecsedi M, Lienert C, Amato MP, Baum K, Bayas A, Brassat D, Brochet B, Confavreux C, Edan G, Färkkilä M, Fasbender P, Fredrikson S, Frontoni M, D'Hooghe M, Hutchinson M, De Keyser J, Kieseier B, Kümpfel T, Laaksonen M, Rio J, Polman C, Roullet E, Vass K, Wandinger KP, Kappos L, and the European Long Term Follow-up Study Group in Interferon ß-1b in Secondary-Progressive MS+10 year follow-up of the European multicenter trial of interferon ß-1b in secondary-progressive MS. Multiple Sclerosis J (2015, in press).
  9. O'Connell K, Langdon D, Tubridy N, Hutchinson M, McGuigan C. Validating the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) tool in an Irish population with multiple sclerosis (MS). Mult Scler Relat Dis 2015; (In press)
  10. McGurgan I,  McGuigan C. Non-melanoma skin cancer risk in azathioprine treated people with Myasthenia Gravis. Brain Behav 2015 (In press)
  11. Lynch DS, Jaunmuktane Z, Sheerin UM, Phadke R, Brandner S, Milonis I, Dean A, Bajaj N, McNicholas N, Costelloe D, Cronin S, McGuigan C, Rossor M, Fox N, Murphy E, Chataway J, Houlden H. Hereditary Leukoencephaloolpathy with Axonal Spheroids: A spectrum of phenotypes from CNS Vasculitis through to Parkinsonism in an adult onset leukodystropht series. J Neurol Neurosurg Psychiatry 2015 (In press)
  12. Williams LJ, Butler JS, Molloy A, McGovern E, Beiser I, Kimmich O, Quinlivan B, O'Riordan S, Hutchinson M, Reilly RB. Young Women do it Better: Sexual Dimorphism in Temporal Discrimination. Front Neurol. 2015 Jul 9;6:160.
  13. Butler JS, Molloy A, Williams L, Kimmich O, Quinlivan B, O'Riordan S, Hutchinson M, Reilly RB. Non-parametric bootstrapping method for measuring the temporal discrimination threshold for movement disorders. J Neural Eng. 2015 Aug;12(4):046026. doi: 10.1088/1741-2560/12/4/046026. Epub 2015 Jun 18.
  14. Molloy A, Williams L, Kimmich O, Butler JS, Beiser I, McGovern E, O'Riordan S, Reilly RB, Walsh C, Hutchinson M. Sun exposure is an environmental factor for the development of blepharospasm. J Neurol Neurosurg Psychiatry. 2015 Apr 22. pii: jnnp-2014-310266. doi: 10.1136/jnnp-2014-310266. [Epub ahead of print]
  15. Sinokrot O, Doyle A, Lonergan R, Kinsella J, McMahon C, FitzGerald SF, McGuigan C. Back pain following a Lumbar Puncture, what's unusual about that? Ir Med J  2015;108:155. 
  16. Tolley K, Hutchinson M, You X, Wang P, Sperling B, Taneja A, Siddiqui, MK, Kinter E. A network meta-analysis of efficacy and evaluation of safety of subcutaneous Pegylated Interferon Beta-1a and injectable therapies for the treatment of relapsing-remitting multiple sclerosis.  PLoS One. 2015 Jun 3;10(6):e0127960.
  17. Hutchinson M. The best clinical paper on multiple sclerosis in 2014: Herodotus and Chataway - Commentary. Mult Scler. 2015 May 6. pii: 1352458515585135
  18. Molloy A, Williams L, Kimmich O, Butler JS, Beiser I, McGovern E, O'Riordan S, Reilly RB, Walsh C, Hutchinson M. Sun exposure is an environmental factor for the development of blepharospasm. J Neurol Neurosurg Psychiatry. 2015 Apr 22. pii: jnnp-2014-310266.
  19. Viglietta V, Miller D, Bar-Or A, Phillips JT, Arnold DL, Selmaj K, Kita M, Hutchinson M, Yang M, Zhang R, Dawson KT, Sheikh SI, Fox RJ, Gold R. Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials. Ann Clin Transl Neurol 2015;2:103-18.
  20. Hutchinson M. The best basic science paper in multiple sclerosis in 2014: Citicoline, remyelination and neuroprotection: Commentary. Mult Scler. 2015 Feb 19. pii: 1352458515573096. [Epub ahead of print] PubMed PMID: 25698170.
  21. Miller DH, Fox RJ, Phillips JT, Hutchinson M, Havrdova E, Kita M, Wheeler-Kingshott CA, Tozer DJ, MacManus DG, Yousry TA, Goodsell M, Yang M, Zhang R, Viglietta V, Dawson KT; CONFIRM study investigators. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. Neurology. 2015;84:1145-52.
  22. Hutchinson M. Any evident MRI T2 lesion activity should guide change of therapy in multiple sclerosis - Commentary. Mult Scler J 2015;21:136-7.
  23. Hutchinson M. We can compare the relative efficacy multiple sclerosis medications by examining the results of independent clinical trials: Commentary. Mult Scler. 2015 Jan;21(1):39-40.
  24. Voloshyna N, Havrdová E, Hutchinson M, Nehrych T, You X, Belachew S, Hotermans C, Paes D. Natalizumab improves ambulation in relapsing-remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis  of AFFIRM. Eur J Neurol 2015 ;22:570-7.